Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer

Journal of Urology

Volumn 177, Issue 4, 2007, Pages 1283-1286

  Raj, Ganesh V ^a   Herr, Harry ^a   Serio, Angel M ^a   Donat, Sherri M ^a   Bochner, Bernard H ^a   Vickers, Andrew J ^a   Dalbagni, Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cystectomy; disease progression; mycobacterium bovis; treatment outcome

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CYSTECTOMY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT CANCER; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; AGED; BCG VACCINE; COHORT STUDIES; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 33947258389     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.11.090     Document Type: Article

References (19)

1. Andius P., and Holmang S. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 93 (2004) 980
2. Herr H.W., Klein E.A., and Rogatko A. Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. Eur Urol 19 (1991) 97
3. Herr H.W., Schwalb D.M., Zhang Z.F., Sogani P.C., Fair W.R., Whitmore Jr. W.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13 (1995) 1404
4. Lamm D.L., Blumenstein B.A., Crawford E.D., Montie J.E., Scardino P., Grossman H.B., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325 (1991) 1205
5. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466
6. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45 (2004) 142
7. Brake M., Loertzer H., Horsch R., and Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163 (2000) 1697
8. Herr H.W. Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin. J Urol 145 (1991) 40
9. Herr H.W., and Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169 (2003) 1706
10. Joudi F.N., and O'Donnell M.A. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 14 (2004) 271
11. Joudi F.N., and Konety B.R. The impact of provider volume on outcomes from urological cancer therapy. J Urol 174 (2005) 432
12. Bianco Jr. F.J., Justa D., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22 (2004) 290
13. Herr H.W. Timing of cystectomy for superficial bladder tumors. Urol Oncol 5 (2000) 162
14. Weiss C., Wolze C., Engehausen D.G., Ott O.J., Krause F.S., Schrott K.M., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?. J Clin Oncol 24 (2006) 2318
15. Luciani L.G., Neulander E., Murphy W.M., and Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 58 (2001) 376
16. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296
17. Nieder A.M., Simon M.A., Kim S.S., Manoharan M., and Soloway M.S. Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology 67 (2006) 737
18. Chang S.S., and Cookson M.S. Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am 32 (2005) 147
19. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141